retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Research Guide: What the Trial Data Reported (2026) Retatrutide, a GIP, GLP-1 and
Description
Not surprisingly, a specific GLP-1 receptor antagonist, exendin [939] amide, accelerates gastric emptying in individuals without diabetes with proportional rises in plasma glucose and insulin (17), indicating that physiological postprandial concentrations of GLP-1 are sufficient to slow gastric emptying substantially
These findings can help in the search for miR-758 biomarkers that target important lipid metabolism pathways [175]
Interestingly, the same study found that, in rats, tirzepatide suppressed lipid intake without affecting sucrose (carbohydrate) consumption in a choice-based assay, implying that the effects of these medications may be macronutrient specific (Geisler et al., 2023)
Glucagon-like peptide 1 receptor agonists and heart failure: The need for further evidence generation and practice guidelines optimization
One study reported that GLP-1 is negatively correlated with body mass index (BMI) and that it appears to increase dentate gyrus neurogenesis based on immunostaining images (Weina et al., 2018)
De Mesquita YLL et al
